Dual ALK and CDK4/6 inhibition demonstrates synergy against neuroblastoma

PURPOSE: Anaplastic Lymphoma Kinase (ALK) is the most frequently mutated oncogene in the pediatric cancer neuroblastoma. We performed an in vitro screen for synergistic drug combinations that target neuroblastomas with mutations in ALK to determine if drug combinations could enhance anti-tumor effic...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Wood, Andrew C., Krytska, Kateryna, Ryles, Hannah, Infarinato, Nicole, Sano, Renata, Hansel, Theodore, Hart, Lori, King, Frederick J., Smith, Timothy R., Ainscow, Edward, Grandinetti, Kathryn B., Tuntland, Tove, Kim, Sunkyu, Caponigro, Giordano, He, You Qun, Krupa, Shiva, Li, Nanxin, Harris, Jennifer L., Mossé, Yaël P.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5457336/
https://ncbi.nlm.nih.gov/pubmed/27986745
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-1114
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados